Sugammadex Reduced the Incidence of Postoperative Pulmonary Complications in Susceptible Patients Identified by ARISCAT Risk Index: Systematic Review and Meta-analysis.
Aspiration pneumonitis
Atelectasis
Pneumonia
Postoperative pulmonary complications
Residual neuromuscular blockade
Respiratory failure
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
19
02
2023
accepted:
27
04
2023
medline:
16
8
2023
pubmed:
23
6
2023
entrez:
23
6
2023
Statut:
ppublish
Résumé
The efficacy of sugammadex on postoperative pulmonary complications (PPCs) in susceptible patients, compared with neostigmine, remains indeterminate. The Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) Group Investigators proposed a risk index for the early identification of susceptible patients, with excellent externally validated discrimination ability. Meta-analytical techniques were applied to evaluate the efficacy of sugammadex on PPCs in patients with ARISCAT-defined risk factors. The study is registered on PROSPERO, number CRD42021261156. We searched PubMed, Scopus, Embase, Cochrane library, GreyNet, and OpenGrey for eligible randomized controlled trials (RCTs) without restricting the language or year of publication. Twelve RCTs consisting of 1182 patients susceptible to PPCs were included. A robust reduction was observed on the incidence of PPCs in susceptible patients who received sugammadex [RR 0.66; 95% CI (0.54, 0.80), p < 0.01], with a low level of between-study heterogeneity (I Low to moderate quality of evidence demonstrated the edge of sugammadex over neostigmine for NMB reversal in reducing the likelihood of PPCs and residual NMB in patients with ARISCAT-defined risk factors. Clinicians may reassess the type of reversal agent when treating patients susceptible to PPCs.
Identifiants
pubmed: 37351811
doi: 10.1007/s12325-023-02535-9
pii: 10.1007/s12325-023-02535-9
doi:
Substances chimiques
Sugammadex
361LPM2T56
Neostigmine
3982TWQ96G
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
3784-3803Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.
Références
Miskovic A, Lumb AB. Postoperative pulmonary complications. Br J Anaesth. 2017;118:317–34.
pubmed: 28186222
doi: 10.1093/bja/aex002
McAlister FA, Bertsch K, Man J, et al. Incidence of and risk factors for pulmonary complications after nonthoracic surgery. Am J Respir Crit Care Med. 2005;171:514–7.
pubmed: 15563632
doi: 10.1164/rccm.200408-1069OC
Khuri SF, Henderson WG, DePalma RG, et al. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg. 2005;242:326–41 (discussion 41–3).
Canet J, Gallart L, Gomar C, et al. Prediction of postoperative pulmonary complications in a population-based surgical cohort. Anesthesiology. 2010;113:1338–50.
pubmed: 21045639
doi: 10.1097/ALN.0b013e3181fc6e0a
Rahe-Meyer N, Berger C, Wittmann M, et al. Recovery from prolonged deep rocuronium-induced neuromuscular blockade: a randomized comparison of sugammadex reversal with spontaneous recovery. Anaesthesist. 2015;64:506–12.
pubmed: 26126940
doi: 10.1007/s00101-015-0048-0
Jones RK, Caldwell JE, Brull SJ, et al. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology. 2008;109:816–24.
pubmed: 18946293
doi: 10.1097/ALN.0b013e31818a3fee
Lawrence VA, Hilsenbeck SG, Mulrow CD, et al. Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery. J Gen Intern Med. 1995;10:671–8.
pubmed: 8770719
doi: 10.1007/BF02602761
Canet J, Sabaté S, Mazo V, et al. Development and validation of a score to predict postoperative respiratory failure in a multicentre European cohort: a prospective, observational study. Eur J Anaesthesiol. 2015;32:458–70.
pubmed: 26020123
doi: 10.1097/EJA.0000000000000223
Mazo V, Sabaté S, Canet J, et al. Prospective external validation of a predictive score for postoperative pulmonary complications. Anesthesiology. 2014;121:219–31.
pubmed: 24901240
doi: 10.1097/ALN.0000000000000334
Jin Y, Xie G, Wang H, et al. Incidence and risk factors of postoperative pulmonary complications in noncardiac Chinese patients: a multicenter observational study in university hospitals. Biomed Res Int. 2015;2015: 265165.
pubmed: 25821791
pmcid: 4363533
doi: 10.1155/2015/265165
Kokotovic D, Degett TH, Ekeloef S, et al. The ARISCAT score is a promising model to predict postoperative pulmonary complications after major emergency abdominal surgery: an external validation in a Danish cohort. Eur J Trauma Emerg Surg. 2022;48:3863–7.
pubmed: 35050387
doi: 10.1007/s00068-021-01826-6
Murphy GS, Szokol JW, Marymont JH, et al. Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit. Anesthesiology. 2008;109:389–98.
pubmed: 18719436
doi: 10.1097/ALN.0b013e318182af3b
Hristovska AM, Duch P, Allingstrup M, et al. The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis. Anaesthesia. 2018;73:631–41.
pubmed: 29280475
doi: 10.1111/anae.14160
Kirmeier, Leva B, Harlet P, et al. Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study. Lancet Respir Med. 2019;7:129–40.
Krause M, McWilliams SK, Bullard KJ, et al. Neostigmine versus sugammadex for reversal of neuromuscular blockade and effects on reintubation for respiratory failure or newly initiated noninvasive ventilation: an interrupted time series design. Anesth Analg. 2020;131:141–51.
pubmed: 31702700
pmcid: 7379749
doi: 10.1213/ANE.0000000000004505
Kheterpal S, Vaughn MT, Dubovoy TZ, et al. Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (STRONGER): a multicenter matched cohort analysis. Anesthesiology. 2020;132:1371–81.
Colquhoun DA, Vaughn MT, Bash LD, et al. Association between choice of reversal agent for neuromuscular block and postoperative pulmonary complications in patients at increased risk undergoing non-emergency surgery: STIL-STRONGER, a multicentre matched cohort study. Br J Anaesth. 2023;130:e148–59.
pubmed: 35691703
doi: 10.1016/j.bja.2022.04.023
Wang JF, Zhao ZZ, Jiang ZY, et al. Influence of sugammadex versus neostigmine for neuromuscular block reversal on the incidence of postoperative pulmonary complications: a meta-analysis of randomized controlled trials. Perioper Med (Lond). 2021;10(1):32.
pubmed: 34538277
doi: 10.1186/s13741-021-00203-6
Yağan Ö, Taş N, Mutlu T, et al. Comparison of the effects of sugammadex and neostigmine on postoperative nausea and vomiting. Braz J Anesthesiol. 2017;67:147–52.
pubmed: 28236862
doi: 10.1016/j.bjan.2015.08.004
Hakimoğlu S, Tuzcu K, Davarcı I, et al. Comparison of sugammadex and neostigmine-atropine on intraocular pressure and postoperative effects. Kaohsiung J Med Sci. 2016;32:80–5.
pubmed: 26944326
doi: 10.1016/j.kjms.2016.01.009
Geldner G, Niskanen M, Laurila P, et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia. 2012;67:991–8.
pubmed: 22698066
doi: 10.1111/j.1365-2044.2012.07197.x
Ba YF, Liu YN, He SH, et al. Analysis of sugammadex for antagonistic neuromuscular block in patients with radical resection of lung cancer under thoracoscope. Zhonghua Yi Xue Za Zhi. 2020;100:213–9.
pubmed: 32008289
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6: e1000100.
pubmed: 19621070
pmcid: 2707010
doi: 10.1371/journal.pmed.1000100
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6: e1000097.
pubmed: 19621072
pmcid: 2707599
doi: 10.1371/journal.pmed.1000097
Jammer I, Wickboldt N, Sander M, et al. Standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine: European Perioperative Clinical Outcome (EPCO) definitions: a statement from the ESA-ESICM joint taskforce on perioperative outcome measures. Eur J Anaesthesiol. 2015;32:88–105.
pubmed: 25058504
doi: 10.1097/EJA.0000000000000118
Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (Updated March 2011). Cochrane handbook for systematic reviews of interventions.
Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
pubmed: 25524443
pmcid: 4383202
doi: 10.1186/1471-2288-14-135
Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
pubmed: 15205295
doi: 10.1136/bmj.328.7454.1490
Jakobsen JC, Gluud C, Winkel P, et al. The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials. BMC Med Res Methodol. 2014;14:34.
pubmed: 24588900
pmcid: 4015863
doi: 10.1186/1471-2288-14-34
Takwoingi Y, Hopewell S, Tovey D, et al. A multicomponent decision tool for prioritising the updating of systematic reviews. BMJ. 2013;347: f7191.
pubmed: 24336453
doi: 10.1136/bmj.f7191
Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358: j4008.
pubmed: 28935701
pmcid: 5833365
doi: 10.1136/bmj.j4008
Yu Y, Wang H, Bao Q, et al. Sugammadex versus neostigmine for neuromuscular block reversal and postoperative pulmonary complications in patients undergoing resection of lung cancer. J Cardiothorac Vasc Anesth. 2022;36:3626–33.
pubmed: 35662514
doi: 10.1053/j.jvca.2022.03.033
Williams WH 3rd, Cata JP, Lasala JD, et al. Effect of reversal of deep neuromuscular block with sugammadex or moderate block by neostigmine on shoulder pain in elderly patients undergoing robotic prostatectomy. Br J Anaesth. 2020;124:164–72.
pubmed: 31780139
doi: 10.1016/j.bja.2019.09.043
Togioka BM, Yanez D, Aziz MF, et al. Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery. Br J Anaesth. 2020;124:553–61.
pubmed: 32139135
doi: 10.1016/j.bja.2020.01.016
Olesnicky B, Doane M, Farrell C, et al. Prevention of postoperative events following reversal with sugammadex or neostigmine (the P-PERSoN Trial): pilot data following early termination of a prospective, blinded, randomised trial. Anesthesiol Res Pract. 2022;2022:4659795.
pubmed: 35844810
pmcid: 9286967
Lee YJ, Oh AY, Koo BW, et al. Postoperative residual neuromuscular blockade after reversal based on a qualitative peripheral nerve stimulator response: a randomised controlled trial. Eur J Anaesthesiol. 2020;37:196–202.
pubmed: 31977627
doi: 10.1097/EJA.0000000000001157
Ledowski T, Szabó-Maák Z, Loh PS, et al. Reversal of residual neuromuscular block with neostigmine or sugammadex and postoperative pulmonary complications: a prospective, randomised, double-blind trial in high-risk older patients. Br J Anaesth. 2021;127:316–23.
pubmed: 34127252
doi: 10.1016/j.bja.2021.04.026
Evron S, Abelansky Y, Ezri T, et al. Respiratory events with sugammadex vs. neostigmine following laparoscopic sleeve gastrectomy: a prospective pilot study assessing neuromuscular reversal strategies. Rom J Anaesth Intensive Care. 2017;24:111–4.
pubmed: 29090263
pmcid: 5642850
Çitil AB, Tuncel ZA, Yapici N, et al. Reversal of rocuronium induced neuromuscular blockade in lung resection surgery: A comparison of sugammadex and neostigmine. Gogus-Kalp-Damar Anestezi ve Yogun Bakim Dernegi Dergisi. 2019;25:23–30.
Carron M, Veronese S, Foletto M, et al. Sugammadex allows fast-track bariatric surgery. Obes Surg. 2013;23:1558–63.
pubmed: 23519634
doi: 10.1007/s11695-013-0926-y
Brueckmann B, Sasaki N, Grobara P, et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study. Br J Anaesth. 2015;115:743–51.
pubmed: 25935840
doi: 10.1093/bja/aev104
Alday E, Muñoz M, Planas A, et al. Effects of neuromuscular block reversal with sugammadex versus neostigmine on postoperative respiratory outcomes after major abdominal surgery: a randomized-controlled trial. Can J Anaesth. 2019;66:1328–37.
pubmed: 31165457
doi: 10.1007/s12630-019-01419-3
Han J, Oh AY, Jeon YT, et al. Quality of recovery after laparoscopic cholecystectomy following neuromuscular blockade reversal with neostigmine or sugammadex: a prospective, randomized, controlled trial. J Clin Med. 2021;10:1–10.
doi: 10.3390/jcm10050938
Hurford WE, Welge JA, Eckman MH. Sugammadex versus neostigmine for routine reversal of rocuronium block in adult patients: a cost analysis. J Clin Anesth. 2020;67: 110027.
pubmed: 32980763
doi: 10.1016/j.jclinane.2020.110027
Carron M, Baratto F, Zarantonello F, et al. Sugammadex for reversal of neuromuscular blockade: a retrospective analysis of clinical outcomes and cost-effectiveness in a single center. Clinicoecon Outcomes Res. 2016;8:43–52.
pubmed: 26937203
pmcid: 4762464
doi: 10.2147/CEOR.S100921
Brett K, Farrah K. CADTH rapid response reports. Sugammadex for the reversal of neuromuscular blockade in surgical patients: a review of clinical effectiveness and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health. Copyright © 2019 Canadian agency for drugs and technologies in health.; 2019.
Berg H. Is residual neuromuscular block following pancuronium a risk factor for postoperative pulmonary complications? Acta Anaesthesiol Scand Suppl. 1997;110:156–8.
pubmed: 9248572
doi: 10.1111/j.1399-6576.1997.tb05541.x
Nieuwenhuijs D, Bruce J, Drummond GB, et al. Ventilatory responses after major surgery and high dependency care. Br J Anaesth. 2012;108:864–71.
pubmed: 22369766
pmcid: 3325049
doi: 10.1093/bja/aes017
Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010;111:120–8.
Cedborg AI, Sundman E, Bodén K, et al. Pharyngeal function and breathing pattern during partial neuromuscular block in the elderly: effects on airway protection. Anesthesiology. 2014;120:312–25.
pubmed: 24162461
doi: 10.1097/ALN.0000000000000043
D’Honneur G, Lofaso F, Drummond GB, et al. Susceptibility to upper airway obstruction during partial neuromuscular block. Anesthesiology. 1998;88:371–8.
pubmed: 9477058
doi: 10.1097/00000542-199802000-00016
Dobson G, Chow L, Filteau L, et al. Guidelines to the practice of anesthesia—revised edition 2020. Can J Anaesth. 2020;67:64–99.
Naguib M, Brull SJ, Kopman AF, et al. Consensus statement on perioperative use of neuromuscular monitoring. Anesth Analg. 2018;127:71–80.
pubmed: 29200077
doi: 10.1213/ANE.0000000000002670
Checketts MR, Alladi R, Ferguson K, et al. Recommendations for standards of monitoring during anaesthesia and recovery 2015: Association of Anaesthetists of Great Britain and Ireland. Anaesthesia. 2016;71:85–93.
pubmed: 26582586
doi: 10.1111/anae.13316
Thilen SR, Weigel WA, Todd MM, et al. 2023 American Society of Anesthesiologists Practice Guidelines for monitoring and antagonism of neuromuscular blockade: a report by the american society of anesthesiologists task force on neuromuscular blockade. Anesthesiology. 2023;138:13–41.
pubmed: 36520073
doi: 10.1097/ALN.0000000000004379
Fuchs-Buder T, Romero CS, Lewald H, et al. Peri-operative management of neuromuscular blockade: A guideline from the European Society of Anaesthesiology and Intensive Care. Eur J Anaesthesiol EJA. 2023;40:82–94.
Eleveld DJ, Kuizenga K, Proost JH, et al. A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg. 2007;104:582–4.
pubmed: 17312212
doi: 10.1213/01.ane.0000250617.79166.7f
Le Corre F, Nejmeddine S, Fatahine C, et al. Recurarization after sugammadex reversal in an obese patient. Can J Anaesth. 2011;58:944–7.
pubmed: 21751072
doi: 10.1007/s12630-011-9554-y
Grosse-Sundrup M, Henneman JP, Sandberg WS, et al. Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. BMJ. 2012;345: e6329.
pubmed: 23077290
pmcid: 3473088
doi: 10.1136/bmj.e6329
Payne JP, Hughes R, Al AS. Neuromuscular blockade by neostigmine in anaesthetized man. Br J Anaesth. 1980;52:69–76.
pubmed: 7378232
doi: 10.1093/bja/52.1.69
Yost CS, Maestrone E. Clinical concentrations of edrophonium enhance desensitization of the nicotinic acetylcholine receptor. Anesth Analg. 1994;78:520–6.
pubmed: 8109771
doi: 10.1213/00000539-199403000-00018
Legendre P, Ali DW, Drapeau P. Recovery from open channel block by acetylcholine during neuromuscular transmission in zebrafish. J Neurosci. 2000;20:140–8.
pubmed: 10627590
pmcid: 6774107
doi: 10.1523/JNEUROSCI.20-01-00140.2000
Herbstreit F, Zigrahn D, Ochterbeck C, et al. Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure. Anesthesiology. 2010;113:1280–8.
pubmed: 20980910
doi: 10.1097/ALN.0b013e3181f70f3d
Bronsert MR, Henderson WG, Monk TG, et al. Intermediate-acting nondepolarizing neuromuscular blocking agents and risk of postoperative 30-day morbidity and mortality, and long-term survival. Anesth Analg. 2017;124:1476–83.
pubmed: 28244947
doi: 10.1213/ANE.0000000000001848
Bulka CM, Terekhov MA, Martin BJ, et al. Nondepolarizing neuromuscular blocking agents, reversal, and risk of postoperative pneumonia. Anesthesiology. 2016;125:647–55.
pubmed: 27496656
doi: 10.1097/ALN.0000000000001279
Keating GM. Sugammadex: a review of neuromuscular blockade reversal. Drugs. 2016;76:1041–52.
pubmed: 27324403
doi: 10.1007/s40265-016-0604-1